M

Mabion SA
WSE:MAB

Watchlist Manager
Mabion SA
WSE:MAB
Watchlist
Price: 8.47 PLN -1.05%
Market Cap: 136.9m PLN
Have any thoughts about
Mabion SA?
Write Note

Relative Value

The Relative Value of one MAB stock under the Base Case scenario is 13.75 PLN. Compared to the current market price of 8.47 PLN, Mabion SA is Undervalued by 38%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MAB Relative Value
Base Case
13.75 PLN
Undervaluation 38%
Relative Value
Price
M
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
65
vs Industry
80
Median 3Y
2
Median 5Y
1.8
Industry
7.6
Forward
1.5
vs History
11
vs Industry
11
Median 3Y
8
Median 5Y
6.3
Industry
22.1
Forward
-167.7
vs History
26
vs Industry
2
Median 3Y
3.5
Median 5Y
-8.5
Industry
21.9
vs History
vs Industry
8
Median 3Y
-4.5
Median 5Y
-11.1
Industry
23.4
vs History
69
vs Industry
43
Median 3Y
3
Median 5Y
2.5
Industry
2.5
vs History
65
vs Industry
73
Median 3Y
1.7
Median 5Y
1.5
Industry
7.5
Forward
1
vs History
65
vs Industry
70
Median 3Y
2.7
Median 5Y
2.2
Industry
9.3
vs History
41
vs Industry
13
Median 3Y
3.9
Median 5Y
2.5
Industry
4.2
Forward
5.2
vs History
34
vs Industry
11
Median 3Y
4.4
Median 5Y
3
Industry
4
Forward
11.2
vs History
28
vs Industry
2
Median 3Y
2.7
Median 5Y
-8.5
Industry
5.9
vs History
12
vs Industry
9
Median 3Y
-3.8
Median 5Y
-6.3
Industry
3.9
vs History
98
vs Industry
52
Median 3Y
1.9
Median 5Y
3.4
Industry
4.5

Multiples Across Competitors

MAB Competitors Multiples
Mabion SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
PL
Mabion SA
WSE:MAB
136.9m PLN 1.2 13.4 2.4 3
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 027 714.7 -180 740.1 -219 476 -216 971.5
US
Abbvie Inc
NYSE:ABBV
310.3B USD 5.6 61.1 15.2 23.4
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 4.4 33.5 16 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 4.1 915.4 10.2 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 9.6 -213.4 21 22.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 852.6 -472.7 -514.8 -501.1
AU
CSL Ltd
ASX:CSL
134.4B AUD 5.7 31.8 19.7 24.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 5.6 16.6 15.1 16.7
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.7 -58.8 -53
NL
argenx SE
XBRU:ARGX
35.8B EUR 19.2 -134.7 -108.8 -79.3
P/S Multiple
Revenue Growth P/S to Growth
PL
M
Mabion SA
WSE:MAB
Average P/S: 3 457 240
1.2
-66%
N/A
FR
Pharnext SCA
OTC:PNEXF
38 027 714.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
34%
0.3
US
E
Epizyme Inc
F:EPE
1 852.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.2
220%
0.1
P/E Multiple
Earnings Growth P/E to Growth
PL
M
Mabion SA
WSE:MAB
Average P/E: 178.6
13.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.1
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
915.4
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -213.4
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
31.8
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -134.7 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
PL
M
Mabion SA
WSE:MAB
Average EV/EBITDA: 14.2
2.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 476 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.8 N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -108.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
PL
M
Mabion SA
WSE:MAB
Average EV/EBIT: 18.6
3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 971.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -501.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.6
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.3 N/A N/A

See Also

Discover More
Back to Top